WO2002085901A8 - Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists) - Google Patents

Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists)

Info

Publication number
WO2002085901A8
WO2002085901A8 PCT/US2002/008268 US0208268W WO02085901A8 WO 2002085901 A8 WO2002085901 A8 WO 2002085901A8 US 0208268 W US0208268 W US 0208268W WO 02085901 A8 WO02085901 A8 WO 02085901A8
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
disease
mammal
formula
treatment
Prior art date
Application number
PCT/US2002/008268
Other languages
French (fr)
Other versions
WO2002085901A1 (en
Inventor
E Jon Jacobsen
Daniel P Walker
Jason K Myers
David W Piotrowski
Vincent E Groppi Jr
Original Assignee
Upjohn Co
E Jon Jacobsen
Daniel P Walker
Jason K Myers
David W Piotrowski
Vincent E Groppi Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co, E Jon Jacobsen, Daniel P Walker, Jason K Myers, David W Piotrowski, Vincent E Groppi Jr filed Critical Upjohn Co
Priority to MXPA03009644A priority Critical patent/MXPA03009644A/en
Priority to AT02764140T priority patent/ATE314367T1/en
Priority to JP2002583428A priority patent/JP2004526788A/en
Priority to CA002439960A priority patent/CA2439960A1/en
Priority to DE60208366T priority patent/DE60208366T2/en
Priority to EP02764140A priority patent/EP1389208B1/en
Publication of WO2002085901A1 publication Critical patent/WO2002085901A1/en
Publication of WO2002085901A8 publication Critical patent/WO2002085901A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

The invention provides compounds of Formula (I): (F) Formula (I) wherein m1 is 0 or 1; m2 is 1 or 2; R¿1? is-H, alkyl, halogenated alkyl, substituted alkyl, cycloakyl, or phenyl; R2 is -H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl, provided that when m?1¿ is 1 at least one of R¿1? and R2 is -H; or a pharmaceutically acceptable salt, pharmaceutical composition, a pure enantiomer or racemic mixture thereof. The invention also provides a method for treating a disease or condition in a mammal, wherein the ≡7 nicotinic acetylcholine receptor is implicated and for treating diseases where there is a sensory-gating deficit in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of Formula (I). These compounds may be in the form of phamaceutical salts or compositions, and may be in pure enantiomeric form or may be racemic mixtures.
PCT/US2002/008268 2001-04-19 2002-04-18 Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists) WO2002085901A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA03009644A MXPA03009644A (en) 2001-04-19 2002-04-18 1 substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor antagonists).
AT02764140T ATE314367T1 (en) 2001-04-19 2002-04-18 SUBSTITUTED AZABICYCLIC UNITS FOR DISEASE TREATMENT (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS)
JP2002583428A JP2004526788A (en) 2001-04-19 2002-04-18 Substituted azabicyclic group for treating diseases (nicotinic acetylcholine receptor antagonist)
CA002439960A CA2439960A1 (en) 2001-04-19 2002-04-18 Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor antagonists)
DE60208366T DE60208366T2 (en) 2001-04-19 2002-04-18 SUBSTITUTED AZABICYCLIC UNIT FOR DISEASE TREATMENT (NICOTINE ACETYLCHOLIN RECEPTOR ANTAGONISTS)
EP02764140A EP1389208B1 (en) 2001-04-19 2002-04-18 Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28495001P 2001-04-19 2001-04-19
US60/284,950 2001-04-19
US34890401P 2001-10-26 2001-10-26
US60/348,904 2001-10-26

Publications (2)

Publication Number Publication Date
WO2002085901A1 WO2002085901A1 (en) 2002-10-31
WO2002085901A8 true WO2002085901A8 (en) 2003-12-24

Family

ID=26962909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/008268 WO2002085901A1 (en) 2001-04-19 2002-04-18 Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists)

Country Status (11)

Country Link
US (1) US6869946B2 (en)
EP (1) EP1389208B1 (en)
JP (1) JP2004526788A (en)
AR (1) AR035817A1 (en)
AT (1) ATE314367T1 (en)
CA (1) CA2439960A1 (en)
DE (1) DE60208366T2 (en)
ES (1) ES2254723T3 (en)
MX (1) MXPA03009644A (en)
PE (1) PE20021019A1 (en)
WO (1) WO2002085901A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273044B2 (en) 2010-05-17 2016-03-01 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
MXPA04007936A (en) * 2002-02-15 2004-11-26 Upjohn Co Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders.
WO2003070732A1 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
HUP0500610A3 (en) 2002-09-25 2013-12-30 Memory Pharm Corp Indazoles, benzothiazoles, and benzoisothiazoles, pharmaceutical compositions comprises thereof and their uses
WO2004052889A1 (en) * 2002-12-06 2004-06-24 Pharmacia & Upjohn Company Llc Compounds as radioligands for the diagnosis of disease
PL378026A1 (en) * 2003-01-22 2006-02-20 Pharmacia & Upjohn Company Llc Treatment of diseases with alpha-7 nach receptor full agonists
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
EP1697378B1 (en) 2003-12-22 2007-11-21 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
WO2005092890A2 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
EP1736156A4 (en) * 2004-04-15 2010-06-16 Eisai R&D Man Co Ltd STABILIZED 4-AMINO-5-CHLORO-N-¬(1R,3r,5S)-8-METHYL-8- AZABICYCLO¬3.2.1 OCT-3-YL -2-¬1-METHYLBUT-2-YNYLOXY -BENZAMIDE CONTAINING COMPOSITION
EP1742944B1 (en) * 2004-04-22 2010-11-10 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
EP1745046B1 (en) 2004-05-07 2011-04-13 Memory Pharmaceuticals Corporation 1 h-indazoles, benzothiazoles, 1,2-benziosoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
AR049401A1 (en) 2004-06-18 2006-07-26 Novartis Ag AZA-BICICLONONANS
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CN101124224A (en) 2004-12-22 2008-02-13 记忆药物公司 Nicotinic alpha-7 receptor ligands and preparation and uses thereof
EP1917265B1 (en) * 2005-08-22 2010-09-29 Targacept, Inc. HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
JP5232374B2 (en) * 2006-09-29 2013-07-10 関東化学株式会社 Method for producing optically active quinuclidinols having a substituent at the 2-position
JP5172124B2 (en) * 2006-09-29 2013-03-27 関東化学株式会社 Method for producing optically active quinuclidinols having a substituent at the 2-position
WO2009146031A1 (en) 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
JP2011520964A (en) * 2008-05-23 2011-07-21 ユニバーシティ・オブ・サウス・フロリダ Method for treating peripheral sensory nerve loss using a compound having nicotinic acetylcholine receptor activity
TW201031664A (en) * 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2012177263A1 (en) * 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
US10183938B2 (en) * 2014-12-16 2019-01-22 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors
CN109320510B (en) * 2018-11-27 2021-04-27 江苏慧聚药业有限公司 Preparation method of Maropitan free base
CN111793017B (en) * 2019-04-04 2024-01-16 广东东阳光药业股份有限公司 Preparation method of lactam compound

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3702324A (en) 1970-06-24 1972-11-07 Stanford Research Inst 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines
FI763021A (en) 1975-11-03 1977-05-04 Thomae Gmbh Dr K
FR2529548A1 (en) 1982-07-02 1984-01-06 Delalande Sa NOVEL DERIVATIVES OF AMINO-3 QUINUCLIDINE, THEIR PROCESS AND THEIR THERAPEUTIC APPLICATION
US5175173A (en) 1983-12-22 1992-12-29 Sun Jung Hui Carboxamides useful as antiemetic or antipsychotic agents
US4593034A (en) 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
US4820715A (en) 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
US4870181A (en) 1985-02-04 1989-09-26 A. H. Robins Company, Incorporated Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2])octan-3-yl)aminobenzamides
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE385517T1 (en) 1985-03-14 1991-07-25 Beecham Group P.L.C., Brentford, Middlesex, Gb MEDICINES FOR TREATING EMERGENCY.
GB8520616D0 (en) 1985-08-16 1985-09-25 Beecham Group Plc Compounds
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
EP0235878A3 (en) 1986-01-16 1989-06-14 Beecham Group Plc Novel compounds
US4717563A (en) 1986-03-05 1988-01-05 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs
HU895334D0 (en) 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
EP0272052B1 (en) 1986-12-16 1992-07-08 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides
US5237066A (en) 1987-02-04 1993-08-17 Delande S.A. Enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their application in therapy
US4835162A (en) 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
DE3822792C2 (en) 1987-07-11 1997-11-27 Sandoz Ag New use of 5HT¶3¶ antagonists
GB8718345D0 (en) 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
US5206246A (en) 1987-10-16 1993-04-27 A. H. Robins Company, Incorporated Anxiolytic-R-n(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides
AU611976B2 (en) 1987-12-24 1991-06-27 John Wyeth & Brother Limited Aroyl urea and carbamic acid derivatives of azabicyclo compounds
FR2625678B1 (en) 1988-01-13 1991-06-07 Delalande Sa ANOREXIGENAL AGENTS BASED ON N- (QUINUCLIDIN-3-YL) -BENZAMIDES OR THIOBENZAMIDES
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (en) 1988-03-29 1989-10-19 Sandoz Ag Esters and amides of indole-, benzo[b]thiophene or benzo[b]furancarboxylic acids or 4-amino-2-methoxybenzoic acids with N-heterocyclic or N-heterobicyclic alcohols or amines, processes for their preparation, pharmaceutical compositions containing them and applicator for administration thereof
DE3878235T2 (en) 1988-08-04 1993-06-03 Synthelabo ANTISCHIZOPHREN EFFECTIVE S-N- (1-AZABICYCLO (2.2.2.) OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES.
EP0353371A1 (en) 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
US4920227A (en) 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Benzobicyclic carboxamide 5-HT3 antagonists
US5290938A (en) 1989-09-15 1994-03-01 Chiron Laboratories A.S. Preparation of S-(-)- and R-(+)-N-(quinuclidinyl-3)-amide
GB8928837D0 (en) 1989-12-21 1990-02-28 Beecham Group Plc Pharmaceuticals
US5057519A (en) 1990-06-11 1991-10-15 Bristol-Myers Squibb Company 5-HT3 antagonists: use in reducing opiate tolerance
US5070095A (en) 1990-12-12 1991-12-03 A. H. Robins Company, Incorporated Substituted 4-(amidino)benzamides of 1-azabicyclo[2.2.2]octan-3- and -4-amine as gastric prokinetic, antiemetic, and anxiolytic agents
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
US5084460A (en) 1990-12-24 1992-01-28 A. H. Robins Company, Incorporated Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
JPH06506467A (en) 1991-03-08 1994-07-21 ローヌ−プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド Polycyclic tertiary amine polyaromatic squalene synthetase inhibitor
US5236931A (en) 1992-03-26 1993-08-17 A. H. Robins Company, Incorporated 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
US5273972A (en) 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
WO1994020617A2 (en) 1993-03-08 1994-09-15 The Salk Institute Biotechnology/Industrial Associates, Incorporated Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
IL109451A0 (en) 1993-04-29 1994-07-31 Zeneca Ltd Heterocyclic derivatives
US5723103A (en) 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
SE9600683D0 (en) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
PT975327E (en) 1997-04-18 2003-11-28 Janssen Pharmaceutica Nv USE OF 5HT3 ANTAGONISTS TO STIMULATE INTESTINAL WASHING
WO2000073431A2 (en) 1999-05-27 2000-12-07 Pharmacia & Upjohn Company Methods and compositions for measuring ion channel conductance
SE9903760D0 (en) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (en) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (en) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273044B2 (en) 2010-05-17 2016-03-01 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9550767B2 (en) 2010-05-17 2017-01-24 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Also Published As

Publication number Publication date
ES2254723T3 (en) 2006-06-16
MXPA03009644A (en) 2004-01-29
PE20021019A1 (en) 2002-11-13
ATE314367T1 (en) 2006-01-15
EP1389208A1 (en) 2004-02-18
WO2002085901A1 (en) 2002-10-31
DE60208366T2 (en) 2006-07-06
US20030055043A1 (en) 2003-03-20
JP2004526788A (en) 2004-09-02
EP1389208B1 (en) 2005-12-28
US6869946B2 (en) 2005-03-22
CA2439960A1 (en) 2002-10-31
DE60208366D1 (en) 2006-02-02
AR035817A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
WO2002085901A8 (en) Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists)
ES2434467T3 (en) Multicyclic compounds and methods for use
WO2003093250A3 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
US5393762A (en) Pharmaceutical agents for treatment of emesis
WO2002016381A3 (en) Composition and method for inhibiting platelet aggregation
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
WO2002016357A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
DE69915027D1 (en) Heteroaromatic bicyclic compounds with anti-cancer effects
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
SE0104334D0 (en) Therapeutic agents
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
BR0214031A (en) Substituted azabicyclic heteroaryl compounds for the treatment of disease
WO2003048164A3 (en) Adenosine a2a receptor antagonists
JP2005506308A5 (en)
WO2007056219A3 (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
SE9901573D0 (en) New compounds
WO2002016356A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
BR0307441A (en) Compounds, process for preparing a compound, pharmaceutical composition, use of such compounds, method for treating and prophylaxis of diseases and method for treating obesity
WO2002016355A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
MXPA04003245A (en) Hydroxypropylamines.
WO1999012532A3 (en) Piperidine derivatives against malaria
MXPA04008152A (en) Azabicyclic compounds for the treatment of disease.
HUT57773A (en) Process for produicng n-(aminocarbonyl)-carbamates related to physostigmine, as well as pharmaceutical compositions comprising such compounds
US5340826A (en) Pharmaceutical agents for treatment of urinary incontinence
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2439960

Country of ref document: CA

Ref document number: 2002338410

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 528964

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/009644

Country of ref document: MX

Ref document number: 2002583428

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002764140

Country of ref document: EP

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

WWP Wipo information: published in national office

Ref document number: 2002764140

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002764140

Country of ref document: EP